These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 31183987)
1. Cabergoline: a review of its use in the inhibition of lactation for women living with HIV. Tulloch KJ; Dodin P; Tremblay-Racine F; Elwood C; Money D; Boucoiran I J Int AIDS Soc; 2019 Jun; 22(6):e25322. PubMed ID: 31183987 [TBL] [Abstract][Full Text] [Related]
2. Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials. Shrateh ON; Kumar KA; Jawed A; Shuja MH; Shamsi HUR; Naasan M J Gynecol Obstet Hum Reprod; 2024 Jun; 53(6):102783. PubMed ID: 38554942 [TBL] [Abstract][Full Text] [Related]
3. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Rains CP; Bryson HM; Fitton A Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332 [TBL] [Abstract][Full Text] [Related]
4. Is Cabergoline Safe and Effective for Postpartum Lactation Inhibition? A Systematic Review. Yang Y; Boucoiran I; Tulloch KJ; Poliquin V Int J Womens Health; 2020; 12():159-170. PubMed ID: 32210637 [TBL] [Abstract][Full Text] [Related]
5. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691 [TBL] [Abstract][Full Text] [Related]
6. Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review. Harris K; Murphy KE; Horn D; MacGilivray J; Yudin MH J Obstet Gynaecol Can; 2020 Mar; 42(3):308-315.e20. PubMed ID: 31285168 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of cabergoline for lactation inhibition in women living with HIV. Boucoiran I; Roy M; Poliquin V; Elwood C; Sheehan NL; Thibaudeau R; Ferreira E; Autmizguine J; Kakkar F; Boucher M; Money D; Tulloch K Int J STD AIDS; 2021 Jun; 32(7):654-661. PubMed ID: 33612017 [TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
10. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition. BMJ; 1991 Jun; 302(6789):1367-71. PubMed ID: 1676318 [TBL] [Abstract][Full Text] [Related]
11. Cabergoline: a new drug for the treatment of hyperprolactinaemia. Ferrari C; Piscitelli G; Crosignani PG Hum Reprod; 1995 Jul; 10(7):1647-52. PubMed ID: 8582955 [TBL] [Abstract][Full Text] [Related]
12. Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline. Melis GB; Mais V; Paoletti AM; Beneventi F; Gambacciani M; Fioretti P Obstet Gynecol; 1988 Mar; 71(3 Pt 1):311-4. PubMed ID: 3279351 [TBL] [Abstract][Full Text] [Related]
13. Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery. Giorda G; de Vincentiis S; Motta T; Casazza S; Fadin M; D'Alberton A Gynecol Obstet Invest; 1991; 31(2):93-6. PubMed ID: 2037265 [TBL] [Abstract][Full Text] [Related]
14. Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi. Buhendwa L; Zachariah R; Teck R; Massaquoi M; Kazima J; Firmenich P; Harries AD Trop Doct; 2008 Jan; 38(1):30-2. PubMed ID: 18302861 [TBL] [Abstract][Full Text] [Related]
15. Treatment of lactating sows with the dopamine agonist Cabergoline: effects on LH and prolactin secretion and responses to challenges with naloxone and morphine. De Rensis F; Quintavalla F; Foxcroft GR Anim Reprod Sci; 1998 May; 51(3):233-47. PubMed ID: 9675405 [TBL] [Abstract][Full Text] [Related]
16. Is pyridoxine effective and safe for post-partum lactation inhibition? A systematic review. AlSaad D; Awaisu A; Elsalem S; Abdulrouf PV; Thomas B; AlHail M J Clin Pharm Ther; 2017 Aug; 42(4):373-382. PubMed ID: 28425124 [TBL] [Abstract][Full Text] [Related]
17. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Kvernmo T; Härtter S; Burger E Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285 [TBL] [Abstract][Full Text] [Related]
18. The efficiency of cabergoline vs pyridoxine for lactation inhibition-a randomized controlled trial. Dayan-Schwartz A; Yefet E; Massalha M; Hosari-Mhameed S; Remer-Gross C; Pasand E; Nachum Z Am J Obstet Gynecol; 2024 May; 230(5):561.e1-561.e8. PubMed ID: 37827268 [TBL] [Abstract][Full Text] [Related]